BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Arunachalam, P. S., Wimmers, F., Mok, C. K. P., Perera, R. A. P. M., Scott, M., & Hagan, T., et al. (2020). Systems biological assessment of immunity to mild versus severe covid-19 infection in humans. Science. Added by: Dr. Enrique Feoli (12/08/2020, 15:14) Last edited by: Dr. Enrique Feoli (12/08/2020, 15:22) |
 |
| Resource type: Journal Article DOI: 10.1126/science.abc6261 ID no. (ISBN etc.): 0036-8075 BibTeX citation key: Arunachalam2020 View all bibliographic details  |
Categories: BioAcyl Corp, Zotero Subcategories: COVID-19 Creators: Alaaeddine, Anderson, Arunachalam, Bosinger, Bristow, Chan, Chik, Choi, Coller, Edupuganti, Feng, Hagan, Huerta, Kazmin, Khatri, Leung, Lv, Maecker, Mok, Paine McCullough, Peiris, Pellegrini, Perera, Pulendran, Rouphael, Scott, Sigal, Tak-Yin Tsang, Upadhyay, Wagh, Wimmers Collection: Science |
Views: 4/298
|
| Abstract |
|
COVID-19 represents a global crisis, yet major knowledge gaps remain about human immunity to SARS-CoV-2. We analyzed immune responses in 76 COVID-19 patients and 69 healthy individuals from Hong Kong and Atlanta. In PBMCs of COVID-19 patients, there was reduced expression of HLA-DR and pro-inflammatory cytokines by myeloid cells, and impaired mTOR-signaling and IFN-α production by plasmacytoid DCs. In contrast, there were enhanced plasma levels of inflammatory mediators, including EN-RAGE, TNFSF14, and oncostatin-M, which correlated with disease severity and increased bacterial products in human plasma. Single-cell transcriptomics revealed no type-I IFN, reduced HLA-DR in myeloid cells of severe patients, and transient expression of IFN-stimulated genes. This was consistent with bulk PBMC transcriptomics, and transient, low plasma IFN-α levels during infection. These results reveal mechanisms and potential therapeutic targets for COVID-19.
|